Company website:http://www.ucb.com

UCB S.A., a biopharmaceutical company, focuses on various diseases in therapeutic areas of neurology and immunology in Belgium and internationally. The company’s products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of partial-onset seizures; and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of vertigo and events associated with ageing; and Xyrem for narcolepsy. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. The company’s development stage products include brivaracetam as adjunctive therapy for epilepsy; tozadenant for Parkinson’s disease; epratuzumab for systemic lupus erythematosus; romosozumab for osteoporosis; UCB4940 for psoriatic arthritis; UCB5857 and UCB7665 for immunological diseases; UCB4942 for drug resistant epilepsy; and dapirolizumab pegol for systemic lupus erythematosus. It has strategic alliances with the Weill Cornell Medical College (U.S.), Sanofi, and Dermira Inc., as well as collaboration and agreement with Neuropore Therapies Inc. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

More info:http://finance.yahoo.com/q?s=UCB.BR

UCB/b - UCB S.A. - KID

Country: Belgium
Currency: EUR
Is shortable: Yes

Trading hours:
Market is closed10:00 - 18:2910:00 - 18:2910:00 - 18:2910:00 - 18:2910:00 - 18:29Market is closed

Interest (annually):
Long positionShort position
–3% -3%

Interest Accrual

Trading Conditions

Temporary margin requirements due to upcoming corporate events:

Margin Calendar